Industry leaders are warning that AI-enabled drug discovery is accelerating candidate generation faster than the clinical trial recruitment system can absorb. Dennis Akkaya, chief growth officer of myTomorrows, argues the recruitment infrastructure is not built for an “AI-fueled” era where molecular discovery compresses timelines but patient access remains the bottleneck. Akkaya points to a mismatch created by more geographically dispersed trials, complex inclusion criteria, and earlier-stage enrollment demands—issues that become more acute as AI matching tools and patient-facing AI increase bottom-up interest before sites are activated. The practical implication is operational: sponsors may need new recruitment models and partnerships to translate faster discovery into faster, representative clinical evidence generation.
Get the Daily Brief